NASDAQ · CRSP
CRISPR Therapeutics AG
$54.26+$0.15 (+0.28%)
CRISPR Therapeutics AG’s quoted price sits in the lower half of its reported 52-week range, 17.76% below the high.
Loading market information…
NASDAQ · BEAM · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Beam Therapeutics Inc.’s forward annual dividend is $0.90 per share, paid quarterly. The forward yield is 3.12% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Beam Therapeutics Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$1.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Beam Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 6, 2025 | -$1.24-11.71% vs estimate | $7.47M-51.86% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | -$1.09+12.8% vs estimate | $30.07M+82.51% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$1.17-3.54% vs estimate | $14.27M-5.64% vs estimate |
|---|
THE ANALYST VIEW
27 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $79.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$54.26+$0.15 (+0.28%)
CRISPR Therapeutics AG’s quoted price sits in the lower half of its reported 52-week range, 17.76% below the high.
$13.23-$0.09 (-0.68%)
Intellia Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.41% below the high.
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
$1.25-$0.05 (-3.85%)
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.97% below the high.
$2.17$0.00 (0.0%)
Fate Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.82% below the high.
$7.44-$0.03 (-0.4%)
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.66% below the high.
$1.17-$0.09 (-7.14%)
Cellectis S.A.’s quoted price sits in the lower half of its reported 52-week range, 78.53% below the high.
$0.45-$0.04 (-9.07%)
Caribou Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.43% below the high.
